@AlexBerenson "Finally tested after 20 years" is just false—Tamiflu has dozens of RCTs, none in the ICU till now. That gap is the actual story. The mortality signal is real but borderline (OR barely clears 1, unblinded, sicker controls). Worth updating ICU practice; not the fraud you think.
@AlexBerenson Also, Tamiflu was never licensed to treat severe infection (ie. the patients in the REMAP-CAP trial) so to imply there's deception on Roche's part is not true
@AlexBerenson Naive reading. Severe flu pathology is largely host inflammation + secondary infection, and you're intervening late in that cascade by the time patients are hospitalized. Doesn't negate the trial—but it bounds how much an antiviral can do at that stage.
@AlexBerenson This is a poorly framed question since there are a lot of factors involved in selecting a comparator. You need to specify the indication. For example, an Ebola vaccine trial would look different then a Rhinovirus trial